care partners | what should you know about the bispecific antibody treatment for myeloma?
Published 4 months ago • 73 plays • Length 25:45Download video MP4
Download video MP3
Similar videos
-
5:58
what myeloma patients need to know about bispecific antibodies
-
2:58
how can bispecific antibody therapy care partners be proactive?
-
3:21
what is the role of a care partner in bispecific antibody therapy?
-
1:55
bispecific antibodies for myeloma | patient eligibility requirements
-
31:04
thriving with myeloma: what you should know about care and treatment
-
2:16
what is the role of bispecific antibody therapies in future myeloma care?
-
2:33
bispecific antibody therapy support | care team members and resources
-
3:43
what treatment is recommended for a newly diagnosed patient?
-
1:33
how has bispecific antibody therapy impacted myeloma care?
-
1:13
what is the role of bispecific antibody therapy in the future of myeloma care?
-
7:15
evolving myeloma treatment options | bispecific antibody therapy
-
32:18
myeloma treatment decisions: what’s right for you?
-
9:34
targeting of myeloma disease progression and bispecific antibody advantages
-
6:08
what should you know about myeloma treatment options?
-
46:34
expert advice for navigating myeloma treatment and care decisions
-
33:24
making myeloma treatment decisions at every stage of care
-
4:54
bispecific antibody therapy | managing side effects
-
2:47
how could clinical trials fit into your myeloma treatment plan?
-
6:15
myeloma maintenance therapy | what patients need to know